GLP-1 Drugs and Medicare: What's Covered, the Bridge Program, and Retirement Planning

Whether Medicare covers your GLP-1 drug depends entirely on the diagnosis for which it is prescribed — not the drug itself. Ozempic (semaglutide) is covered under Part D when prescribed for Type 2 diabetes. The same molecule sold as Wegovy for obesity is not covered under standard Part D — but beginning July 1, 2026, a new CMS pilot program called the Medicare GLP-1 Bridge will make Wegovy, Foundayo, and Zepbound available to eligible beneficiaries at $50 per month.

This is the most rapidly changing area of Medicare policy in 2026. The coverage rules, eligibility criteria, and program timelines are current as of May 19, 2026.

The Statutory Barrier

Before understanding what Medicare does cover, it is essential to understand why the gap exists. Medicare Part D has been prohibited by federal statute from covering drugs prescribed specifically for weight loss since the program was created in 2003. This is not a coverage policy preference — it is a hard legal constraint embedded in the Social Security Act. The same statute that prohibits weight-loss drug coverage also prohibits coverage for drugs used for cosmetic purposes, hair growth, and smoking cessation.

The Biden administration attempted to remove this barrier through a proposed 2026 Part D rule that would have expanded Medicare coverage of GLP-1s to all people with obesity. The Trump administration declined to finalize that rule in April 2025, citing cost projections of approximately $35 billion from 2026 to 2034. The statutory prohibition remains in place. Making GLP-1 coverage for obesity permanent requires an act of Congress — multiple bills have been introduced (the TREAT and REDUCE Acts) but as of May 2026, none have passed.

What Part D Covers Today

The coverage picture is not binary. Part D covers GLP-1 drugs when they are prescribed for an FDA-approved indication other than weight loss.

Covered under standard Part D:

• Ozempic and Rybelsus (semaglutide): Covered when prescribed for Type 2 diabetes blood sugar management, and for cardiovascular risk reduction in patients with T2D and established cardiovascular disease
• Mounjaro (tirzepatide): Covered when prescribed for Type 2 diabetes management and CV risk reduction in T2D patients
• Victoza (liraglutide) and Trulicity (dulaglutide): Covered for Type 2 diabetes
• Wegovy (semaglutide for obesity): Covered when prescribed specifically for cardiovascular risk reduction in adults with obesity or overweight plus established cardiovascular disease — a coverage pathway that opened in June 2024 following the SELECT trial, which showed Wegovy reduced major cardiovascular events by 20% in non-diabetic patients
• Zepbound (tirzepatide for obesity): Covered when prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity

Not covered under standard Part D:

• Any GLP-1 prescribed for weight loss without a diabetes, cardiovascular, or sleep apnea qualifying diagnosis
• Saxenda (liraglutide for obesity): Prescribed for obesity only — no other FDA-approved indication, no Part D coverage
• Wegovy or Zepbound for obesity alone (without CV disease or sleep apnea) — this is the Bridge program's target population

For beneficiaries whose GLP-1 is covered under standard Part D, the 2026 out-of-pocket cap of $2,000 applies to total Part D drug costs — significantly limiting exposure even for high-cost drugs. Prior authorization is typically required and must cite the covered indication clearly.

The Medicare GLP-1 Bridge Program — Launching July 1, 2026

On July 1, 2026, CMS is launching the Medicare GLP-1 Bridge — a short-term demonstration program that provides eligible Part D beneficiaries access to select GLP-1 drugs at $50 per month, outside the standard Part D benefit and payment flow. The program runs through December 31, 2027.

The Bridge covers three drugs: Wegovy (all formulations, including the newly approved tablet), Foundayo (all formulations), and Zepbound (KwikPen formulation only — the auto-injector pen is not included at launch). Ozempic and Mounjaro are not in the Bridge program for obesity — those drugs are covered via standard Part D when prescribed for diabetes, not through the Bridge.

The $50 copay applies regardless of dosage level — a beneficiary on the highest maintenance dose pays the same $50/month as someone on the lowest starting dose. No deductible applies to Bridge program costs. Per CMS guidance, Part D sponsors do not need to opt into the Bridge for eligible beneficiaries to access it — the program operates as a separate pathway.

CMS estimates approximately 29 million Medicare beneficiaries would qualify for the Bridge, though roughly 16 million already have access through other covered indications (T2D, CV disease, sleep apnea).

Bridge Eligibility — Three BMI and Condition Tiers

Eligibility is structured in three tiers based on BMI and qualifying conditions.

Tier 1 — BMI ≥ 27 with high-risk conditions: Prediabetes, established cardiovascular disease, or a history of heart attack or stroke qualifies a beneficiary with a BMI of 27 or above.

Tier 2 — BMI ≥ 30 with metabolic conditions: Heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease qualifies a beneficiary with a BMI of 30 or above.

Tier 3 — BMI ≥ 35, no additional condition required: Severe obesity alone — a BMI of 35 or higher — qualifies without any additional diagnosis.

Beneficiaries who want GLP-1 drugs for weight loss only with a BMI below 35 and no qualifying condition are not eligible for the Bridge. They remain in the coverage gap: no standard Part D coverage and no Bridge access. Full retail cost — approximately $1,060–$1,350 per month for injectables — applies.

For Retirees Transitioning from Employer Coverage to Medicare

This is the transition risk most people do not anticipate.

Employer health plans often cover GLP-1 drugs for obesity — sometimes at modest cost-sharing. When a retiree turns 65 and transitions to Medicare, their employer coverage ends and Medicare rules apply. If the GLP-1 was prescribed for obesity alone (no T2D, no CV disease, no qualifying condition), the transition to Medicare means the drug is no longer covered under the retiree's standard Part D plan — at any price — unless they are eligible for the Bridge.

This cliff creates a common scenario: a person who has been successfully managing weight or metabolic conditions on a GLP-1 through employer coverage suddenly faces $1,000+ monthly drug costs at Medicare enrollment. The Bridge program partially addresses this for eligible beneficiaries — but the eligibility requirements must be met, and the Bridge only runs through December 2027.

What to do before transitioning to Medicare: Have your physician document your BMI and any qualifying conditions (prediabetes, hypertension, CV disease, kidney disease) in your medical record. Clarify which diagnosis is on the prescription. If you have Type 2 diabetes, ensure the T2D indication is on the Ozempic or Mounjaro prescription — not just an off-label obesity indication. The difference between "prescribed for T2D" and "prescribed for weight loss" is the difference between $2,000/year out of pocket and $16,200/year.

Retirement Budget Planning for GLP-1 Costs

The financial stakes are high enough to warrant explicit budget treatment in a retirement plan. Three scenarios cover most situations:

If you have T2D or qualifying CV/sleep apnea indication: Budget up to $2,000/year for your GLP-1 drug under Part D's out-of-pocket cap. Prior auth delays are common — budget time as well as money for the approval process.

If you are eligible for the Bridge (July 2026–December 2027): Budget $600/year ($50 × 12 months) through December 2027 — a known, fixed expense. After December 2027, the cost is uncertain pending Congressional action or BALANCE Model launch. Build a contingency in your plan for the possibility that post-Bridge costs return to full retail or Part D tier pricing.

If you have no qualifying condition and BMI under 35: The full retail cost of $12,000–$16,000+ per year must be budgeted as a healthcare expense or accepted as unavailable. This is not a manageable long-term expense for most retirees on fixed income. The clinical conversation with your doctor about alternative approaches is as relevant as the financial one.

What Happens After December 31, 2027

The Bridge program is explicitly temporary — CMS calls it a "short-term demonstration." Three scenarios determine what happens to GLP-1 coverage for obesity after it ends:

Congress passes legislation: Bills removing the statutory prohibition on covering weight-loss drugs would make GLP-1 coverage for obesity permanent under Part D. The projected cost of $35 billion over eight years and current Congressional priorities make near-term passage uncertain, but the legislation exists and could move if a larger healthcare bill provides a vehicle.

CMS launches the BALANCE Model: The originally planned 2027 BALANCE Model pilot would allow Part D plans to voluntarily cover GLP-1s for obesity at $50/month in a 5-year program. CMS has delayed this to give insurers time to study Bridge utilization data. If launched, enrollees in participating plans would maintain the $50/month cost structure — but not all plans would participate.

Coverage ends with the Bridge: If neither Congress nor CMS acts, coverage for obesity-indication GLP-1s ends on January 1, 2028 and cost reverts to full retail for non-T2D/CV indications. Retirees currently managing on Bridge coverage at $50/month should treat this as a real planning scenario and have a conversation with their physician about what happens if the drug becomes unaffordable.

Prior Authorization and Practical Access

Prior authorization for GLP-1 drugs under Part D is common. Documentation requirements typically include a confirmed T2D, CV, or qualifying diagnosis in the medical record, evidence that other treatment approaches have been tried (for some plans), and a current prescription specifying the covered indication.

For the Bridge program, CMS has indicated the process will be simpler than standard Part D prior auth — but specific pharmacy workflows will vary and may take time to standardize after July 1. If you are planning to access the Bridge starting in July, submit a prescription in advance, not on July 1 itself.

Manufacturer patient assistance programs remain available for Medicare beneficiaries who do not qualify for Bridge coverage and cannot afford retail costs — Novo Nordisk's Patient Assistance Program and Eli Lilly's Insulin Value Program both accept Medicare beneficiaries under income thresholds that are worth checking.

Important Notes

• The Bridge program operates outside standard Part D — the $50/month Bridge copay does not count toward the Part D $2,000 out-of-pocket cap. These are separate buckets.
• Medicare Advantage plans that include Part D drug coverage are also subject to the Bridge — CMS guidance is that Part D sponsors do not need to opt in. Verify with your MA plan's pharmacy benefit in late June before assuming automatic access.
• If you are enrolled in both Medicare and Medicaid (dual eligible), approximately a dozen states have opted to provide GLP-1 coverage for obesity through Medicaid in 2026. Check your state Medicaid program for current coverage.
• The $2,000 Part D out-of-pocket cap (a 2023 Inflation Reduction Act provision) means that for covered indications (T2D, CV, sleep apnea), annual out-of-pocket GLP-1 cost is capped — even if the drug costs $12,000+ at retail. This substantially improves affordability for Medicare beneficiaries who have a qualifying diagnosis.
• This is education, not medical or coverage advice. Coverage decisions are highly individual and depend on your specific diagnosis, drug, Part D plan formulary, and documentation. Verify your specific situation with your physician and your Part D plan before July 1, 2026.

In ModernRetire

The Healthcare Cost Planner under Health -> Medicare includes a GLP-1 module:

1. Enter your BMI, diagnosis, and current GLP-1 drug — the planner identifies which coverage pathway applies (standard Part D, Bridge eligible, or uninsured) and calculates your projected annual cost under each scenario.
2. The Bridge Eligibility Checker walks through all three BMI/condition tiers and returns a clear eligible / not eligible determination with the documentation your physician will need to confirm.
3. The Post-2027 Scenario Planner shows your healthcare budget under three post-Bridge outcomes (permanent coverage, BALANCE Model pilot, coverage cliff) so you can model the financial range and build appropriate contingency into your retirement plan.
4. If you are transitioning from employer coverage to Medicare and currently taking a GLP-1, the Medicare Transition Checklist flags the drug coverage cliff and prompts you to confirm your prescription's indicated diagnosis before your Medicare start date.